MEF, a recently identified member of the E74 family of ETS-related transcription factors, is a strong transcriptional activator of cytokine gene expression. Using a green fluorescent protein gene reporter plasmid regulated by an MEF-responsive promoter, we determined that the transcriptional activity of MEF is largely restricted to the G 1 phase of the cell cycle. MEF-dependent transcription was suppressed by the expression of cyclin A but not by cyclin D or cyclin E. This effect was due to the kinase activity generated by cyclin A expression, as co-expression of the cyclin-dependent kinase inhibitors p21 or p27, or a dominant negative form of CDK2 (DNK2), abrogated the reduction of MEF transcriptional activity by cyclin A. Cyclin A-CDK2 phosphorylated MEF protein in vitro more efficiently than cyclin D-CDK4 or cyclin E-CDK2, and phosphorylation of MEF by cyclin A-CDK2 reduced its ability to bind DNA. We determined one site of phosphorylation by cyclin A-CDK2 at the C terminus of MEF, using mass-spectrometry; mutation of three serine or threonine residues in this region significantly reduced phosphorylation of MEF by cyclin A and reduced cyclin A-mediated suppression of its transactivating activity. These amino acid substitutions also reduced the restriction of MEF activity to G 1 . Phosphorylation of MEF by the cyclin A-CDK2 complex controls its transcriptional activity during the cell cycle, establishing a novel link between the ETS family of proteins and the cell cycle machinery.
Critical events occur during the G 1 phase of the cell cycle that determine whether a cell will continue proliferating or will withdraw from the cell cycle and undergo differentiation or apoptosis (1) . Transcription factors play a key role in these events, and their activity can be modified during G 1 by a variety of intracellular and extracellular signals that alter their amount or their ability to interact with other proteins or with DNA (2).
Cyclin-dependent kinases (CDKs) 1 play a critical role in the commitment of a cell to proliferate; commitment occurs during the G 1 to S transition, at a time called the restriction point. CDKs are activated by their association with regulatory subunits known as cyclins. The transition from G 1 to S requires the temporal activation of cyclin D-CDK4 or cyclin D-CDK6, cyclin E-CDK2, and cyclin A-CDK2, while cyclin B-CDK1 (CDC2) is essential for the G 2 /M transition (3) . Cyclin D-and cyclin E-dependent kinases regulate the activity of the transcription factor E2F, which controls the expression of a variety of genes necessary for DNA synthesis (4, 5) . Cyclin-CDK complexes phosphorylate the retinoblastoma gene product (Rb), releasing E2F from its sequestration by Rb and allowing E2F to transactivate genes essential for S phase, such as DNA polymerase-␣, thymidine kinase, and cyclins E and A. Both cyclin E-CDK2 and cyclin A-CDK2 can form quaternary complexes with the Rb-related protein p107 and with E2F during S phase; the exact function of these complexes remains obscure (6, 7) .
The ETS family of transcription factors has been shown to play key roles in the growth and differentiation of both hematopoietic and nonhematopoietic cells. Disruption of PU.1 or Ets-1 by homologous recombination can block the development of granulocyte and monocyte lineages or reduce the number and proliferative capacity of mature T cells (8 -12) . Overexpression of Fli-1 or PU.1 can generate murine erythroleukemias (13, 14) , whereas morphogenic abnormalities that resemble Down's syndrome are seen in transgenic mice that overexpress Ets-2 (15) . ETS genes are involved in numerous, specific chromosomal translocations found in human leukemias and sarcomas (e.g. (16 -20) .
TEL-AML1, TEL-PDGFR␤, EWS-FLI1, EWS-ERG, and EWS-ETV1
We recently cloned an ETS-related factor called MEF (myeloid elf-1-like factor), which is expressed in a variety of hematopoietic and nonhematopoietic cells (21) . MEF binds to DNA in a sequence-specific fashion and potently transactivates the granulocyte-macrophage colony-stimulating factor and IL-3 promoters. We have demonstrated that MEF physically and functionally interacts with members of the AML1/RUNX1 family of hematopoietic regulatory proteins and showed that its activity is repressed by the t(8;21) AML-associated fusion protein AML1-ETO (22) . Very recent studies of MEF homozygous null mice (Ϫ/Ϫ), generated by homologous recombination, dem-onstrate a role for MEF in hematopoietic stem cell and NK-T cell behavior.
2 ELF-1, another member of the E74 family of ETS proteins, is highly homologous to MEF in the ETS (DNA binding) domain, and ELF-1 binds to identical sequences in the granulocyte macrophage-colony-stimulating factor and IL-3 promoters, but has minimal transactivating activity (23) (24) (25) . ELF-1 binds to Rb via an LXCXE motif, and this interaction is disrupted by Rb phosphorylation (26) . Although not formally shown, it has been suggested that the function of ELF-1 is regulated by its interactions with Rb.
This led us to examine whether the activity of MEF was also regulated during the cell cycle, and in this report we describe the phosphorylation of MEF, by the cyclin A-CDK2 complex, and the in vitro and in vivo physical interactions between cyclin A and MEF. Furthermore, we have shown that the DNA binding and transcriptional activating properties of MEF are regulated by cyclin A-CDK2, largely restricting MEF function to the G 1 /S phase of the cell cycle. MEF activity, like E2F, is linked to the cell cycle. Our ongoing search for MEF-regulated target genes should identify important cell cycle-regulated proteins.
MATERIALS AND METHODS
Plasmid Construction-To create reporter gene plasmids that were transcriptionally responsive to MEF, double-stranded complementary oligonucleotides (called APET) containing enhancer sequences from the human IL-3 promoter, were subcloned in front of the herpes simplex virus thymidine kinase (Tk) minimal promoter followed by either the CAT or the green fluorescent protein (GFP) reporter gene. The sequence of the APET oligonucleotide is CTCAGTGAGCTGAGTCAGGCTTC-CCCTTCCTGCCACAGGG, whereas the sequence of the mutant APET oligonucleotide, that lacks an ETS binding site (ETS mutant APET oligonucleotide), is CCTCAGTGAGCTGAGTCAGGCTgagCTcgacGC-CACAGGG (mutated sequences are indicated in lowercase, bold letters). Sequence-specific binding of MEF to the APET oligonucleotide, but not the ETS mutant APET oligonucleotide, has been demonstrated previously (21) .
Four distinct reporter plasmids were used to assess the transcriptional activity of MEF; two contained one copy of the APET or ETS mutant APET oligonucleotide subcloned in front of the Tk promoter and the CAT gene (named APET or ETS mutant APET-Tk-CAT), and two contained the same sequences subcloned upstream of the GFP gene (isolated from the pGFP-C3 plasmid (CLONTECH) and named APETor ETS mutant APET-Tk-GFP). The following cDNAs were subcloned into a CMV (cytomegalovirus) promoter-based expression plasmid: MEF, mouse cyclin D1 (27) , human cyclin E (28), human cyclin A (29), human cyclin B (30), human WAF1 p21 (31), mouse Kip p27 (32) , and a dominant negative form of CDK2 (33). A mutant MEF, that lacks three potential phosphorylation sites (MEF-TRI-A), was created using a standard polymerase chain reaction-based mutagenesis method; MEF-TRI-A contains three amino acid substitutions (serine 640, threonine 642, and serine 648 were all changed to alanine). Following dideoxy DNA sequencing, to confirm that all three mutations were correctly introduced, the MEF-TRI-A cDNA was subcloned into the CMV promoter-based expression plasmid.
Transient Transfection Assays-COS cells were cultured in Iscove's modified Dulbecco's medium with 10% fetal bovine serum (FBS), 2 mM glutamine, and antibiotics and were trypsinized and re-plated the day prior to transfection. Ten g of the empty, MEF, or MEF-TRI-A expression plasmid and 10 g of reporter plasmid (APET-Tk-CAT or ETS mutant APET-Tk-CAT or GFP) were introduced into COS cells with or without 5 g of an expression plasmid for the cyclins or cyclin-dependent kinase inhibitors by electroporation, using a Gene Pulser (Bio-Rad) set at 300 mV and 960 microfarads. The total amount of plasmid DNA was kept constant in each sample by adding empty pCMV5 expression vector. Two micrograms of the reporter plasmid pEGFP-C3 (CLON-TECH) (which is regulated by the MEF unresponsive CMV promoter), rather than 10 g, were used for the experiments shown in Fig. 1 , because of the stronger fluorescent signal. 20 -24 h after transfection, the cells were harvested for CAT assay (performed as described previously (21)) or for the detection of GFP expression. To assay for green fluorescence-positive cells, COS cells transfected with a GFP or EGFP reporter plasmid were trypsinized 24 h after electroporation, washed with phosphate-buffered saline (PBS), and resuspended in phenol redfree Dulbecco's modified Eagle's medium (high glucose) with 5% FBS. The intensity of green fluorescence in these cells was analyzed, and cells were sorted into various fractions using a FACScan (Becton Dickinson) fluorescent-activated cell sorter. The cell cycle profile was analyzed using a FACStar (Becton Dickinson) flow cytometer, after nuclear preparation and staining with ethidium bromide (34) .
Preparation of Anti-MEF Antiserum-Anti-MEF antiserum was generated by immunizing rabbits with the C-terminal portion of bacterially expressed MEF protein (amino acids 420 -663) generated by the pET-30(b) expression plasmid (Novagen) and purified using nickel-agarose beads. The antiserum was affinity-purified using Affi-Gel 10 (Bio-Rad) columns coupled to the same antigen.
Expression of Proteins in Sf9 Insect Cells Using Recombinant Baculoviruses-The coding region of the MEF cDNA was subcloned into the pBlueBac-HisB plasmid (Invitrogen), and recombinant baculovirus was prepared that expresses MEF protein with a histidine tag. Recombinant baculoviruses that express cyclin A and CDK2 were kindly provided by D. O. Morgan (35) , and those that express cyclin D and CDK4 were kindly provided by C. J. Sherr (36) .
Labeling The immunoprecipitations were performed as described above. After four washes with Nonidet P-40 lysis buffer, the immune complexes were released from protein A-Sepharose beads by adding 100 l of denaturation buffer (50 mM Tris, pH 8, 0.5% SDS, 1 mM DTT) and heating at 95°C for 5 min. Protein complexes were sequentially immunoprecipitated, using specific antibodies, in IP-2 buffer (150 mM NaCl, 20 mM Tris, pH 8, 1% Nonidet-P 40, 0.25 mM phenylmethylsulfonyl fluoride), were recovered with protein A-Sepharose beads and were washed four times with IP-2 buffer. After SDS-PAGE, the gels were dried and exposed to Kodak XAR film at room temperature.
To detect the in vivo interaction between endogenous MEF and the cyclin A-CDK2 complex, Kasumi-1 cells (a human acute myeloid leukemia cell line) were synchronized at the G 1 /S phase of the cell cycle by treatment with 2 mM hydroxyurea for 24 h. The cells were then lysed with NETN buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris, pH 8.0, and 1% Nonidet P-40), and the lysates were subjected to immunoprecipitations using rabbit preimmune serum, anti-MEF, anti-CDK2, and anticyclin A antibodies, respectively. The immunoprecipitates were electrophoretically separated using SDS-12% PAGE, and MEF protein was detected by immunoblotting using an anti-MEF antiserum.
In Vitro Kinase Assay-Full-length MEF protein was expressed in Sf9 cells using recombinant baculovirus, then purified and fixed on nickel-agarose beads (Novagen). After 48 h of infection, cells were washed with PBS, then lysed with high salt lysis buffer (500 mM NaCl, 20 mM Tris-HCl, pH 8, 0.5% Nonidet-P) containing proteinase inhibitors (10 g/ml leupeptin, 10 g/ml aprotinin, 0.2 mM phenylmethylsulfonyl fluoride), and clarified by centrifugation. Imidazole was added to the lysate to a final concentration of 5 mM, then the cellular extract was mixed with nickel-agarose beads for 18 h. After washing with 1ϫ binding buffer (500 mM NaCl, 20 mM Tris-HCl, pH 8, 20 mM imidazole) and 1ϫ washing buffer (500 mM NaCl, 20 mM Tris-HCl, pH 8, 60 mM imidazole), beads carrying MEF protein were resuspended in NT buffer (150 mM NaCl, and 20 mM Tris-HCl, pH 8).
Two microliters of Sf9 cellular extract containing a combination of cyclin D2 and CDK4, cyclin E and CDK2, or cyclin A and CDK2 were incubated with 0.2 g of GST-Rb (Santa Cruz) or 20 l of nickel-agarose beads bearing histidine-tagged MEF protein in a 30-l kinase reaction 2 D. Lacorazza et al., unpublished data. mixture (50 mM HEPES-KOH, pH 7.5, 10 mM MgCl 2, 1 mM DTT, 2.5 mM EGTA, 10 mM ␤-glycerophosphate, 0.1 mM NaVO 4 , 1 mM NaF, 20 M lithium-ATP, and [␥-32 P]ATP) for 30 min at 30°C. After adding 10 l of 4ϫ SDS sample buffer, samples were boiled for 5 min at 95°C, then separated by SDS-PAGE, and autoradiography was performed. The relative intensity of each band was measured using a Fuji phosphoimager, and the ratio of MEF:Rb phosphorylation for each reaction was calculated. In later experiments, a histidine-tagged mutant MEF protein (MEF-TRI-A) was evaluated for its ability to be phosphorylated by cyclin A-CDK2 in vitro.
Electrophoretic Mobility Shift Assays (EMSAs)-MEF, cyclin A, and CDK2 proteins were expressed in Sf9 cells, in various combinations, using recombinant baculoviruses. After 48 h of infection, cells were washed with PBS, resuspended in buffer S (20 mM HEPES-KOH, pH 7.5, 50 mM KCl, 1 mM DTT) containing proteinase inhibitors and phosphatase inhibitors (mentioned above), then disrupted by repeated freeze-thawing. The extracts were clarified by centrifugation, and the amount of MEF protein in each extract was assessed by Western blotting, using serially diluted samples.
Complementary strands of the APET oligonucleotide were annealed and labeled using polynucleotide kinase (Roche Molecular Biochemicals) and [␥-
32 P]ATP. One ng of labeled oligonucleotide was incubated with Sf9 cellular lysates containing a constant amount of MEF protein with or without cyclin A and/or CDK2 protein in a 25-l reaction mixture containing 20 mM HEPES-NaOH, pH 7.9, 50 mM KCl, 0.5 mM EDTA, 2 mM DTT, 10% glycerol, and 2 g of poly(dI-dC) for 30 min on ice. Samples were loaded onto a 5% nondenaturing polyacrylamide gel and run in 0.5ϫ TBE buffer (Tris borate-EDTA) at room temperature. Gels were dried, and autoradiography was performed with an intensifying screen at Ϫ70°C.
Determination of Phosphorylation Sites Using Mass SpectrometryThe Sf9 cells infected with recombinant baculoviruses that overexpress MEF protein, and the cyclin A-CDK2 complex, were lysed with K-lysis buffer (150 mM NaCl, 50 mM HEPES-KOH, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 0.5% Nonidet-P 40, 10% glycerol) containing the proteinase inhibitors mentioned above. MEF and the cyclin A-CDK2 complex were immunoprecipitated and recovered from the lysates using specific antibodies and protein A-Sepharose beads. In vitro kinase reactions were performed by mixing protein A-Sepharose beads bearing MEF and cyclin A-CDK2 in a 50-l kinase reaction mixture at 30°C. After a 1-h incubation, followed by brief centrifugation, the protein A-Sepharose beads were resuspended in 45 l of 2ϫ SDS sample buffer, then heated at 95°C for 5 min. Samples were separated by SDS-PAGE, and the proteins were transferred to a nitrocellulose membrane.
The bands of interest were excised from the nitrocellulose and processed for internal amino acid sequence analysis as described (37) , with modifications (38) . Briefly, in situ proteolytic cleavage was done using 0.2 g of trypsin (modified sequencing grade; Promega) in 25 l of 100 mM NH 4 HCO 3 (supplemented with 1% Zwittergent 3-16) for 2 h at 37°C. The resulting peptide mixture was reduced and S-alkylated with, 0.1% ␤-mercaptoethanol (Bio-Rad) and 0.3% 4-vinyl pyridine (Aldrich), respectively, and fractionated by reversed phase HPLC (39) . An enzyme blank was done on an equally sized strip of nitrocellulose.
Purified, 32 P-labeled peptides (selected by scintillation counting) were analyzed by a combination of automated Edman degradation and matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry; details about this combined approach can be found elsewhere (39, 40) . Chemical sequencing (on 90% of the sample) was done using a model 477A instrument from Applied Biosystems. Stepwise liberated phenylthiohydantoin-derivative acids were identified using an "on-line" 120A HPLC system (Applied Biosystems) equipped with a PTH C18 (2.1 ϫ 220 mm; 5-micron particle size) column (Applied Biosystems). Instruments and procedures were optimized for femtomole level phenylthiohydantoin-derivative analysis as described (39, 40) . Theoretical monoisotopic masses of predicted tryptic MEF peptides were calculated using ProComp version 1.2 software (obtained from Dr. P. C. Andrews, University of Michigan, Ann Arbor, MI); to account for possible phosphorylation, 79.366 Da (or multiples thereof) was added to the predicted masses for comparison with experimental values.
RESULTS

The Transcriptional Activity of MEF Varies during the Cell
Cycle-Several methods have been used to study changes in the transcriptional activity of proteins during the cell cycle, but these often involve serum deprivation or the use of reversible agents that block the cell cycle. Although these techniques synchronize the growth of cells in culture, they can alter cell physiology in other subtle or not so subtle ways. To overcome this problem, we developed a reporter system based on the detection of GFP (41), whose expression is governed by an MEF-responsive promoter.
The reporter plasmid, called APET-Tk-GFP, contains MEFresponsive enhancer sequences (which we call APET) derived from the human IL-3 5Ј-flanking region in front of the herpes simplex virus Tk promoter. The sequence-specific binding of MEF to these IL-3 sequences was shown previously (21) , and this reporter system accurately measures the transcriptional activity of MEF. The APET-Tk-GFP reporter plasmid has minimal background activity in the absence of MEF, and a mutant APET-Tk-GFP reporter plasmid that lacks the MEF binding site has minimal activity in the presence or absence of MEF (see below). These features enable us to fractionate cell populations by fluorescence-activated cell sorting (FACS) according to the level of GFP expression, which correlates directly with the amount of MEF activity.
COS cells were transfected with the APET-Tk-GFP reporter plasmid and an MEF expression plasmid and were separated by FACS sorting into three fractions 24 h later, based on the level of green fluorescence (Fig. 1A) . Cell nuclei in each fraction were then stained with ethidium bromide, to analyze the cell cycle distribution by flow cytometry. Approximately 13% of the total cells (the sum of the high (H), middle (M), and low (L) fractions) exhibited significant fluorescence, reflecting the transactivating activity of MEF. Cells with the greatest intensity of fluorescence showed a 2.0-or 3.6-fold enrichment in the number of cells in the G 1 phase of the cell cycle, compared with the unsorted total cell population (high (H)/total) or the cells with low intensity (high (H)/low (L)), respectively (Fig. 1A) . Thus, the transactivating activity of MEF, as defined by the intensity of fluorescence, clearly correlated with the proportion of cells in G 1 . As shown in Table I , cells transfected with the APET-Tk-GFP reporter plasmid and an empty expression plasmid did not contain a significant number of cells in the high, medium, or low intensity fractions, and cells transfected with the MEF expression plasmid and the ETS mutant APET-Tk-GFP reporter plasmid (with mutated MEF binding sites) did not display any high intensity fluorescence. The peak activity of MEF during G 1 suggests that MEF transactivating activity is regulated in a cell cycle-dependent fashion, being higher in G 1 than during the rest of the cell cycle. Another explanation is that overexpression of MEF in COS cells causes the accumulation of cells in G 1 .
To distinguish between these two possibilities, we transfected COS cells with 2 g of a GFP reporter plasmid that is driven by the CMV promoter (which is not regulated by MEF) and 10 g of either the MEF expression plasmid or the empty expression vector (Fig. 1B) . DNA content was measured in the total and the high, medium, and low intensity GFP-positive fractions; 52-56% of the transfected cells were GFP-positive, reflecting the transfection efficiency. In this setting, the presence or absence of MEF did not alter the distribution of cells throughout the cell cycle (Fig. 1B) . This suggests that overexpression of MEF does not cause accumulation of COS cells in G 1 . Rather, MEF transcriptional activity appears to be regulated during the cell cycle, causing the significant enrichment of the green fluorescence signal in G 1 .
Modulation of the Transcriptional Activity of MEF by Cyclin A-To further investigate the link between MEF activity and the G 1 phase of the cell cycle, we examined whether the forced expression of cyclin D, E, A, or B affected the transactivating activity of MEF using a CAT reporter plasmid under the control of the same MEF-responsive enhancer element (APET-Tk-CAT). MEF transactivated the APET-Tk-CAT plasmid 8 -12-fold in COS cells, but it did not transactivate the mutant CAT reporter construct that lacks functional MEF binding sites (data not shown). Co-expression of cyclin A reduced the level of MEF-dependent transactivation by 75% ( Fig. 2A) , whereas coexpression of cyclin D1, E, or B did not significantly alter transactivation by MEF. Thus, cyclin A, which is not expressed during G 1 (29) , specifically down-regulates the transcriptional activity of MEF. To demonstrate that this action of cyclin A depends on the activity of the cyclin A-associated kinase, we co-transfected COS cells with expression plasmids for the cyclindependent kinase inhibitors p21 or p27 (42), together with cyclin A, MEF, and APET-Tk-CAT. Both p21 and p27 completely abrogated the inhibitory effect of cyclin A on MEF activity, but had minimum effects on the activating activity of MEF in the absence of cyclin A overexpression (Fig. 2B) . Furthermore, expression of a dominant negative mutant of CDK2 (DNK2), which binds to cyclin A but lacks kinase activity, also abolished the effect of cyclin A on MEF activity (Fig. 2B) . These findings clearly demonstrate that cyclin A-dependent kinase activity, presumably CDK2, negatively regulates the transactivating activity of MEF.
Phosphorylation of MEF by the cyclin A-CDK2 complex. The transcriptional regulatory activity, DNA binding activity, or multiprotein subunit assembly of several ETS proteins can be controlled, at least in part, by phosphorylation. The ERK, JNK, and p38 members of the mitogen-activated protein kinase (MAPK) families, and casein kinase II, can phosphorylate and regulate these activities of ETS proteins such as ELK-1, SAP-1, or PU.1 (43) (44) (45) (46) To determine whether CDK can phosphorylate MEF in vitro, we expressed histidine-tagged MEF protein (His-MEF) in Sf9 insect cells using recombinant baculovirus. Following purification, either GST-tagged retinoblastoma protein (GST-Rb) or His-MEF was incubated with extracts from Sf9 cells infected with cyclin D2-CDK4, cyclin E-CDK2, or cyclin A-CDK2 recombinant baculoviruses in the presence of [␥-32 P]ATP (Fig. 3A) . Extracts containing cyclin D2-DK4, cyclin E-DK2, or cyclin A-CDK2 efficiently phosphorylated GST-Rb, as expected (3). In contrast, MEF was most efficiently phosphorylated by cyclin A-CDK2; cyclin D2-CDK4 had negligible activity, whereas cyclin E-CDK2 demonstrated an intermediate ability to phosphorylate MEF. Control extracts, from uninfected Sf9 cells, did not phosphorylate His-MEF or GST-Rb. The ratio of MEF phosphorylation to Rb phosphorylation by each cyclin-CDK complex demonstrates that MEF is a preferred substrate for the in vitro kinase activity of cyclin A-CDK2.
MEF Physically Interacts with Cyclin A-Both cyclin A and cyclin E can form stable complexes with p107, which is then phosphorylated by the cyclin A-CDK2 or cyclin E-CDK2 complex (4). D-type cyclins specifically associate with Rb (36), demonstrating that CDK substrates can bind with high affinity to the relevant cyclins. This prompted us to examine whether MEF can bind directly to cyclin A. MEF and cyclin A, with or without CDK2, were expressed in Sf9 cells using recombinant baculoviruses. The Sf9 cells were then labeled with [ 35 S]methionine, and cell lysates were immunoprecipitated using anticyclin A, anti-CDK2, or anti-MEF antibodies. A 100-kDa protein (MEF) was detected in total cell lysates and immunoprecipitates from cells infected with an MEF-expressing baculovirus using anti-MEF antiserum; this protein comigrates on SDS-PAGE with bacterially expressed and in vitro   FIG. 1. MEF activity is highest during the G 1 phase of the cell cycle. A, COS cells were co-transfected with the MEF expression plasmid and the APETTk-GFP reporter plasmid, so that GFP expression was regulated by the activating activity of MEF. GFP-positive cells were fractionated (into low (L), medium 
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translated MEF, and it is not observed in uninfected Sf9 cell lysates (data not shown). Similarly, expression of cyclin A or CDK2 in Sf9 cells generated a 60-or 33-kDa protein, as detected using the respective, specific antibody (Fig. 3B) . Following co-expression of MEF and cyclin A in Sf9 cells, the anti-MEF antibody co-immunoprecipitated cyclin A, and reciprocally, the anti-cyclin A antibody co-immunoprecipitated MEF protein (Fig. 3B, upper panel) , demonstrating that these proteins are present in the same complex in Sf9 cells. No interaction was observed between MEF and CDK2 when these proteins were co-expressed in Sf9 cells without expressing cyclin A (Fig. 3B, lower panel) . The association between MEF and cyclin A was also detected in COS cells transfected with expression plasmids for MEF, cyclin A, and p21 proteins (Fig. 4A) . COS cells transfected with these expression plasmids were labeled with [ 35 S]methionine, lysed, and then sequential immunoprecipitation was performed using specific antibodies against cyclin A or MEF. Immune complexes recovered using the first antibody and protein A-Sepharose were released in the presence of 0.5% SDS, then a second immunoprecipitation was performed using these supernatants and a second antibody. Cyclin A was immunoprecipitated using the anti-MEF antibody (lane 1), and MEF was immunoprecipitated using an antibody against cyclin A (lane 2), clearly demonstrating the association of MEF with cyclin A in vivo.
To show the in vivo interaction between endogenous MEF and cyclin A or CDK2, we synchronized Kasumi-1 cells at S phase with hydroxyurea, to enrich cells expressing cyclin A. Kasumi-1 cell lysates were then prepared and subjected to immunoprecipitation with pre-immune serum, or anti-MEF, anti-CDK2, or anti-cyclin A antisera. As shown in A-CDK2 . A, the APET-Tk-CAT reporter plasmid and the MEF expression plasmid were co-transfected with individual cyclin expression plasmids into COS cells. The CAT activity generated by the APET-Tk-CAT plasmid in the presence of the empty pCMV5 expression vector was assigned the value of 1. B, the p21, p27, or DNK2 expression plasmids were co-transfected with the MEF and cyclin A expression plasmids, and the generated CAT activity was measured. The combination of expression plasmids used in these transfections is shown under each bar. Standard errors are shown for each combination of plasmids.
duced Phosphorylation-To determine how the transcriptional activity of MEF is reduced by the presence of cyclin A and its associated kinase activity, we performed EMSA using Sf9 total cellular extracts that contain either MEF alone or MEF with CDK2 Ϯ cyclin A (Fig. 5A) . Cell extracts containing MEF protein generate a specific gel-shift band using the APET oligonucleotide (21) (lane 2). Extracts containing MEF and CDK2, without overexpressed cyclin A, generated a gel-shift band of similar intensity as extracts containing MEF alone (lane 3), whereas the DNA binding activity of the extract was significantly reduced when MEF was co-expressed with CDK2 and cyclin A (lane 4), which suggests that phosphorylation of MEF protein by cyclin A-CDK2 decreases its DNA binding activity. A uniform amount of MEF was present in each of the last three lanes (Fig. 5B) . Extracts from Sf9 cells expressing cyclin A and CDK2 contained significant cyclin A-associated histone H1 kinase activity, while infected cells expressing MEF, or MEF plus CDK2, had negligible histone H1 kinase activity (data not shown).
Determination of the Sites in MEF Phosphorylated by the Cyclin A-CDK2 Complex-To address the effect of phosphorylation on the regulation of MEF activity, we have begun to define the sites in the MEF protein that are phosphorylated by the cyclin A-CDK2 complex. We first performed an in vitro kinase reaction using purified MEF and purified cyclin A-CDK2 complex (these proteins were expressed in Sf9 cells and purified using specific antibodies against MEF or cyclin A, respectively), in the presence of 32 P-labeled ATP. The radiolabeled phosphorylated MEF protein or the unlabeled control MEF protein was separated by SDS-PAGE and transferred to a nitrocellulose membrane. These proteins were then digested in situ with trypsin, and the resulting fragments separated by micro-bore reversed phase HPLC. Aliquots of each tryptic peptide peak, collected during HPLC analysis of digested 32 Plabeled MEF ("P-MEF"), were counted, and the total counts/ min was calculated for the entire fraction volume. Two adjacent 
peptide peaks, P-MEF-T37 and -T38 (shown in Fig. 6, top  panel) , contained nearly all of the 32 P counts above background: 13,025 cpm and 5,736 cpm, respectively. T38 appears as a small shoulder on the T37 peak, and almost certainly represents chromatographic tailing. These fractions, together with the closely eluting P-MEF-T39, were taken for mass and chemical sequencing analysis; tryptic peptides that eluted in corresponding positions during HPLC of an MEF control digest (Fig. 6, bottom panel) , namely MEF-T19, -T20, and -T21, were also analyzed.
Nearly all of the counts were eluted from the nitrocellulose after the tryptic digest, and the radioactivity was largely confined to a single peak during HPLC, identifying a single phosphorylated tryptic peptide. Sequence analysis of P-MEF-T37 indicated the presence of a trypsin autolytic fragment and an unphosphorylated tryptic peptide (containing amino acids (aa) 353-390 in the MEF protein (data not shown)); these findings were subsequently confirmed by mass analysis. We also observed an extra mass value (m/z ϭ 1880.916), which corresponded very well to a different, predicted, singly phosphorylated tryptic MEF peptide (from aa 641-657). A nearly identical mass value (m/z ϭ 1880.884) was also found in the small P-MEF-T38 peak. The presence of this phospho-peptide could not be shown directly by chemical sequencing of peaks P-MEF-T37 or -T38, because the amounts of protein were below the limits of detection using phenylthiohydantoin-derivative identification. We did, however, find the unphosphorylated form of the 641-657 aa phospho-peptide in the P-MEF-T39 peak; as expected, the unphosphorylated form was contained within a peak that eluted slightly more slowly than the phosphorylated form of aa 641-657 (found in peaks 37 and 38). These results identify one site of cyclin A-CDK2 phosphorylation in MEF that is contained within the region 641-657; due to technical limitations in the analysis of tryptic peptides, this methodology cannot rule out phosphorylation at other sites in MEF. Table II) . To examine the effect of phosphorylation at these sites on the transcriptional activity of MEF, we mutated these residues to alanine residues (Table II) and tested the ability of the mutant MEF-TRI-A protein to be phosphorylated by cyclin A-CDK2 and be down-regulated by cyclin A overexpression. We also tested its G 1 restricted activity. All of the studies demonstrate partial abrogation of the effect of cyclin A.
Mutation of C-terminal Serine and Threonine Residues Partially Abrogates the G 1 Restriction of MEF Activity and Decreases Phosphorylation by Cyclin
The mutant MEF-TRI-A protein was co-expressed in COS cells with the APET-Tk-GFP reporter plasmid. GFP positive cells were collected and fractionated as described above; the cell cycle distribution of the cells in each fraction (high, medium, and low green fluorescence) was analyzed and compared with the results generated by wild type MEF protein (Table II) We evaluated the ability of the MEF-TRI-A protein to be phosphorylated in vitro by cyclin A-CDK2 (Fig. 7) . Multiple experiments demonstrate that phosphorylation of MEF-TRI-A by cyclin A-CDK2 is markedly reduced compared with the wild type MEF protein (shown in Fig. 7A ). Densitometric analysis of these experiments (Fig. 7C) shows that phosphorylation is reduced by ϳ75%, and Coomassie Blue staining demonstrated that there was roughly an equal amount of MEF-GST fusion 641 S P T P A P F S P F N P T S L I K 657 MEF-TRI-A: 641 A P A P A P F A P F N P T S L I K 657
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protein in each lane (Fig. 7B) . When the MEF-TRI-A mutant was tested in co-transfection assays with cyclin A, its downregulation by cyclin A was ϳ40% less than the down-regulation of wild type MEF (data not shown). Taken in aggregate, these data show that the three Ser/Thr residues within aa 641-657 are largely, but not completely, responsible for the regulation of MEF activity by cyclin A.
DISCUSSION
Cell cycle-dependent regulation of transcription factor function is critical for the coordination of a variety of cell fates, including differentiation and programmed cell death. Cyclin A is required for the initiation and maintenance of the S phase of the cell cycle (48, 49) . Expression of cyclin A and its associated kinase activity are minimal during G 1 , begin accumulating at the G 1 /S boundary, and reach a maximum during G 2 (50) . The suppression of MEF activity by cyclin A-dependent phosphorylation and the cell cycle-dependent regulation of cyclin A suggests that MEF activity decreases during S phase. This hypothesis was confirmed by using a GFP reporter-based cell sorting method that fractionates transfected cells on a single cell basis according to the level of MEF activity (without chemically perturbing them) as we demonstrated that the transactivating activity of MEF is largely restricted to the G 1 phase of the cell cycle. Cells fractionated for high MEF activity are enriched in G 1 , which likely reflects the increasing activity of the cyclin A-CDK2 complex during movement into S phase, which leads to inhibition of MEF transactivating activity.
The regulation of MEF activity by the cyclin A-CDK2 complex is further demonstrated by the physical interaction between cyclin A and MEF, which was observed between the endogenous MEF and cyclin A proteins in a human leukemia cell line. We confirmed that this interaction is direct using Sf9 cells and COS cells. MEF is a preferred substrate for the cyclin A-CDK2 kinase complex in vitro and CDK inhibitors or a dominant negative mutant of CDK2 abrogated cyclin A-dependent suppression of the MEF activity in transfected cells. These observations strongly suggest that cyclin A-CDK2 is a modulator of MEF activity in vivo, by direct phosphorylation. Although we have demonstrated that the cyclin E-CDK2 complex can modestly phosphorylate MEF, we saw no obvious effect of the cyclin E-CDK2 complex on the transcriptional activity of MEF. Several transcription factors, including Rb, can be sequentially phosphorylated by different cyclin-CDK complexes during the cell cycle (51) . Therefore, we do not rule out the possibility that MEF can also be phosphorylated by cyclin E-CDK2 (or even other cyclin-CDK complexes) in vivo.
The percentage of GFP-positive cells in each fractionated cell population depends on the number of cells in that phase of the cell cycle, the activity of MEF, and the relative rates of synthesis and decay of the GFP protein. Since we have shown that expression of MEF does not cause a significant accumulation of COS cells in G 1 , the amount of fluorescence in G 1 largely reflects the transcriptional activity of MEF during that phase. The amount of GFP fluorescence in S phase likely reflects some carryover of GFP protein expression from late G 1 phase and some residual MEF activity present at early or middle S phase, which would decrease by the gradually increasing cyclin A-CDK2 activity throughout the S phase. Mutations that eliminate the G 1 restriction of MEF activity would be expected to increase the amount of GFP expression in S phase, and after defining a 17-amino acid region of MEF (residue 641-657) that is phosphorylated in vitro by cyclin A-CDK2, we demonstrated that mutation of three potential cyclin A-CDK2 phosphorylation sites in the C terminus of MEF did just that. These aa substitutions greatly attenuated the cell cycle-dependent regulation of MEF activity in vivo, as reflected by the shift of GFP protein expression from G 1 toward S phase (Table II) . These mutations, which block phosphorylation in this region by cyclin A-CDK2 (and potentially other cellular kinases), do not completely eliminate phosphorylation of MEF by cyclin A-CDK2 nor do they completely abrogate the G 1 restriction of its activity. Future studies will determine whether phosphorylation of MEF by cyclin A-CDK2 occurs at any of the four additional potential phosphorylation sites found in MEF (Fig. 8) .
It is still unclear how the cyclin A-dependent phosphorylation of MEF decreases its DNA binding activity and whether other cell cycle-dependent mechanisms could also control MEF function. These questions await the determination of the crystal structure of MEF protein and further investigation. MEF is most similar to ELF-1 among the ETS family members, sharing homology in its DNA binding domain and N-terminal region (21) . However, unlike ELF-1, MEF does not have a consensus LXCXE motif for binding to Rb. This suggests that cell cycle progression from G 1 to S regulates the activities of ELF-1 and MEF by distinct mechanisms.
Cyclin-CDK-dependent inactivation of transcriptional modulators like Rb, involvement of a CDK complex (cyclin H-CDK7) in the basic transcriptional apparatus, or direct phosphorylation of transcription factors by the CDKs, as we describe in this report, can regulate transcription during the cell cycle (2) . Phosphorylation by cyclin A-CDK2 has been shown to stimulate the activity of p53 (52, 53) and B-myb (54 -56) , but inhibit the DNA binding activity of E2F (57) (58) (59) and of MEF (this report). The G 1 -restricted activity of MEF may be critical to control the transcription of genes required for cell fate determination during the restriction point, which can be influenced by cytokines and other extracellular factors (1) . The importance of ETS family proteins in the differentiation and proliferation of hematopoietic lineages, as demonstrated by gene targeting experiments and our preliminary analysis of MEF homozygous null (Ϫ/Ϫ) mice, suggests a role for MEF in both hematopoietic stem cell and lymphoid cell biology. Once cells pass the restriction point, the cyclin A-CDK2 activity that accumulates during late G 1 through S will turn off gene transcription that is dependent on MEF. Alternatively, as cells commit to withdraw from the cell cycle and initiate a differentiation program, cyclin A expression and its associated kinase activity remain low, allowing MEF to constitutively stimulate the expression of genes involved in growth arrest and/or differentiation. We are using gene chip microarrays to identify direct MEF target genes, but our study also confirms the importance of post-translational changes in regulating protein function.
